Knock-down of oncohistone H3F3A-G34W counteracts the neoplastic phenotype of giant cell tumor of bone derived stromal cells.

[1]  Yong-Koo Park,et al.  Giant cell tumor of bone: updated molecular pathogenesis and tumor biology. , 2018, Human pathology.

[2]  G. Rennert,et al.  Cancer-driving H3G34V/R/D mutations block H3K36 methylation and H3K36me3–MutSα interaction , 2018, Proceedings of the National Academy of Sciences.

[3]  J. Fletcher,et al.  Immunohistochemistry for histone H3G34W and H3K36M is highly specific for giant cell tumor of bone and chondroblastoma, respectively, in FNA and core needle biopsy , 2018, Cancer cytopathology.

[4]  E. Wardelmann,et al.  Diagnostic tools in the differential diagnosis of giant cell-rich lesions of bone at biopsy , 2018, Oncotarget.

[5]  Wei Li,et al.  Histone H3.3 G34 Mutations Alter Histone H3K36 and H3K27 Methylation In Cis. , 2018, Journal of molecular biology.

[6]  Junhong Han,et al.  Mechanism of cancer: Oncohistones in action. , 2018, Journal of genetics and genomics = Yi chuan xue bao.

[7]  Hu Li,et al.  Global H3.3 dynamic deposition defines its bimodal role in cell fate transition , 2018, Nature Communications.

[8]  K. Helin,et al.  Oncohistones: drivers of pediatric cancers , 2017, Genes & development.

[9]  Christopher R. Schmidt,et al.  The histone variant H3.3 G34W substitution in giant cell tumor of the bone link chromatin and RNA processing , 2017, Scientific Reports.

[10]  David T. W. Jones,et al.  Histone 3.3 hotspot mutations in conventional osteosarcomas: a comprehensive clinical and molecular characterization of six H3F3A mutated cases , 2017, Clinical Sarcoma Research.

[11]  Dylan M. Marchione,et al.  Impaired H3K36 methylation defines a subset of head and neck squamous cell carcinomas , 2017, Nature Genetics.

[12]  S. Thibodeau,et al.  The histone H3.3K36M mutation reprograms the epigenome of chondroblastomas , 2016, Science.

[13]  B. Garcia,et al.  Histone H3K36 mutations promote sarcomagenesis through altered histone methylation landscape , 2016, Science.

[14]  Keith L. Ligon,et al.  Spatial and temporal homogeneity of driver mutations in diffuse intrinsic pontine glioma , 2016, Nature Communications.

[15]  Shawn M. Gillespie,et al.  Insulator dysfunction and oncogene activation in IDH mutant gliomas , 2015, Nature.

[16]  C. Allis,et al.  Every amino acid matters: essential contributions of histone variants to mammalian development and disease , 2014, Nature Reviews Genetics.

[17]  M. Kaminski,et al.  Mutations in linker histone genes HIST1H1 B, C, D, and E; OCT2 (POU2F2); IRF8; and ARID1A underlying the pathogenesis of follicular lymphoma. , 2014, Blood.

[18]  Kuniaki Saito,et al.  H3F3A K27M mutations in thalamic gliomas from young adult patients. , 2014, Neuro-oncology.

[19]  M. Stratton,et al.  Distinct H3F3A and H3F3B driver mutations define chondroblastoma and giant cell tumor of bone , 2013, Nature Genetics.

[20]  B. Garcia,et al.  Inhibition of PRC2 Activity by a Gain-of-Function H3 Mutation Found in Pediatric Glioblastoma , 2013, Science.

[21]  A. Ashworth,et al.  Histone H3.3. mutations drive pediatric glioblastoma through upregulation of MYCN. , 2013, Cancer discovery.

[22]  E. Delbarre,et al.  DAXX-dependent supply of soluble (H3.3–H4) dimers to PML bodies pending deposition into chromatin , 2013, Genome research.

[23]  H. Mankin,et al.  Giant Cell Tumor of Bone , 2013, The Journal of the American Academy of Orthopaedic Surgeons.

[24]  David T. W. Jones,et al.  Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma , 2012, Nature.

[25]  E. Kavanagh,et al.  Histone onco-modifications , 2011, Oncogene.

[26]  S. Rafii,et al.  Distinct Factors Control Histone Variant H3.3 Localization at Specific Genomic Regions , 2010, Cell.

[27]  M. Szendrői,et al.  Local recurrence of giant cell tumor of bone after intralesional treatment with and without adjuvant therapy. , 2008, The Journal of bone and joint surgery. American volume.